Stock data
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX) reported revenue of US$30.91M and net income of -US$74.28M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$30.91M | — | -US$86.39M | -US$74.28M | — |
| 2024 | US$22.60M | — | -US$102.68M | -US$86.62M | — |
| 2023 | US$34.16M | — | -US$107.91M | -US$98.43M | — |
| 2022 | US$19.23M | — | -US$117.14M | -US$108.88M | — |
| 2021 | US$1.32M | — | -US$100.73M | -US$101.32M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$16.07M | -US$7.19M | — |
| 2026-03-31 | US$3.27M | -US$19.88M | — |
| 2025-12-31 | US$9.25M | -US$21.66M | — |
| 2025-09-30 | US$8.15M | -US$15.85M | — |
| 2025-06-30 | US$7.56M | -US$17.94M | — |
| 2025-03-31 | US$5.95M | -US$18.83M | — |
| 2024-12-31 | US$2.86M | -US$19.50M | — |
| 2024-09-30 | US$7.81M | -US$19.12M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.